Compare LITS & DETX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LITS | DETX |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.7M | 23.9M |
| IPO Year | N/A | N/A |
| Metric | LITS | DETX |
|---|---|---|
| Price | $0.95 | $4.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 357.1K | 16.1K |
| Earning Date | 05-19-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.69 | $3.80 |
| 52 Week High | $3.03 | $4.25 |
| Indicator | LITS | DETX |
|---|---|---|
| Relative Strength Index (RSI) | 52.21 | 11.57 |
| Support Level | $0.79 | N/A |
| Resistance Level | $0.99 | $4.25 |
| Average True Range (ATR) | 0.07 | 0.21 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 70.96 | 24.45 |
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.